156 related articles for article (PubMed ID: 17576061)
41. Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.
Ott GR; Asakawa N; Lu Z; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos JM; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(5):1577-82. PubMed ID: 18242982
[TBL] [Abstract][Full Text] [Related]
42. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
Xue CB; Chen XT; He X; Roderick J; Corbett RL; Ghavimi B; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Trzaskos J; Newton RC; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2004 Sep; 14(17):4453-9. PubMed ID: 15357971
[TBL] [Abstract][Full Text] [Related]
44. Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Duan JJ; Lu Z; Xue CB; He X; Seng JL; Roderick JJ; Wasserman ZR; Liu RQ; Covington MB; Magolda RL; Newton RC; Trzaskos JM; Decicco CP
Bioorg Med Chem Lett; 2003 Jun; 13(12):2035-40. PubMed ID: 12781190
[TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
Ramurthy S; Costales A; Jansen JM; Levine B; Renhowe PA; Shafer CM; Subramanian S
Bioorg Med Chem Lett; 2012 Feb; 22(4):1678-81. PubMed ID: 22264479
[TBL] [Abstract][Full Text] [Related]
46. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
[TBL] [Abstract][Full Text] [Related]
47. Heterocyclic core analogs of a direct thrombin inhibitor.
Blizzard TA; Singh S; Patil B; Chidurala N; Komanduri V; Debnath S; Belyakov S; Crespo A; Struck A; Kurtz M; Wiltsie J; Shen X; Sonatore L; Arocho M; Lewis D; Ogletree M; Biftu T
Bioorg Med Chem Lett; 2014 Feb; 24(4):1111-5. PubMed ID: 24461292
[TBL] [Abstract][Full Text] [Related]
48. Novel methods and strategies in the discovery of TACE inhibitors.
Murumkar PR; Giridhar R; Yadav MR
Expert Opin Drug Discov; 2013 Feb; 8(2):157-81. PubMed ID: 23231541
[TBL] [Abstract][Full Text] [Related]
49. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
[TBL] [Abstract][Full Text] [Related]
50. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
Chen JM; Jin G; Sung A; Levin JI
Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
[TBL] [Abstract][Full Text] [Related]
51. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
[TBL] [Abstract][Full Text] [Related]
52. Design and synthesis of novel benzoheterocyclic derivatives as human acrosin inhibitors by scaffold hopping.
Chen Q; Tian W; Han G; Qi J; Zheng C; Zhou Y; Ding L; Zhao J; Zhu J; Lv J; Sheng C
Eur J Med Chem; 2013 Jan; 59():176-82. PubMed ID: 23220646
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological evaluation of heterocycle containing adamantane 11beta-HSD1 inhibitors.
Yeh VS; Patel JR; Yong H; Kurukulasuriya R; Fung S; Monzon K; Chiou W; Wang J; Stolarik D; Imade H; Beno D; Brune M; Jacobson P; Sham H; Link JT
Bioorg Med Chem Lett; 2006 Oct; 16(20):5414-9. PubMed ID: 16899366
[TBL] [Abstract][Full Text] [Related]
54. Chemical-physical analysis of a tartrate model compound for TACE inhibition.
Banchelli M; Guardiani C; Tenori E; Menichetti S; Caminati G; Procacci P
Phys Chem Chem Phys; 2013 Nov; 15(43):18881-93. PubMed ID: 24089197
[TBL] [Abstract][Full Text] [Related]
55. Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs.
Le GT; Abbenante G
Curr Med Chem; 2005; 12(25):2963-77. PubMed ID: 16378499
[TBL] [Abstract][Full Text] [Related]
56. Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.
Girijavallabhan VM; Chen L; Dai C; Feltz RJ; Firmansjah L; Li D; Kim SH; Kozlowski JA; Lavey BJ; Kosinski A; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Tong L; Wong MK; Yang DY; Yang L; Yu W; Zhou G; Guo Z; Orth P; Madison V; Bian H; Lundell D; Niu X; Shah H; Sun J; Umland S
Bioorg Med Chem Lett; 2010 Dec; 20(24):7283-7. PubMed ID: 21106451
[TBL] [Abstract][Full Text] [Related]
57. Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1.
Stachel SJ; Coburn CA; Rush D; Jones KL; Zhu H; Rajapakse H; Graham SL; Simon A; Katharine Holloway M; Allison TJ; Munshi SK; Espeseth AS; Zuck P; Colussi D; Wolfe A; Pietrak BL; Lai MT; Vacca JP
Bioorg Med Chem Lett; 2009 Jun; 19(11):2977-80. PubMed ID: 19409780
[TBL] [Abstract][Full Text] [Related]
58. Synthesis, screening and docking of small heterocycles as glycogen phosphorylase inhibitors.
Schweiker SS; Loughlin WA; Lohning AS; Petersson MJ; Jenkins ID
Eur J Med Chem; 2014 Sep; 84():584-94. PubMed ID: 25062009
[TBL] [Abstract][Full Text] [Related]
59. N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.
Musso DL; Andersen MW; Andrews RC; Austin R; Beaudet EJ; Becherer JD; Bubacz DG; Bickett DM; Chan JH; Conway JG; Cowan DJ; Gaul MD; Glennon KC; Hedeen KM; Lambert MH; Leesnitzer MA; McDougald DL; Mitchell JL; Moss ML; Rabinowitz MH; Rizzolio MC; Schaller LT; Stanford JB; Tippin T; Warner JR; Whitesell LG; Wiethe RW
Bioorg Med Chem Lett; 2001 Aug; 11(16):2147-51. PubMed ID: 11514157
[TBL] [Abstract][Full Text] [Related]
60. Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.
Maingot L; Elbakali J; Dumont J; Bosc D; Cousaert N; Urban A; Deglane G; Villoutreix B; Nagase H; Sperandio O; Leroux F; Deprez B; Deprez-Poulain R
Eur J Med Chem; 2013 Nov; 69():244-61. PubMed ID: 24044937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
